Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
Clin Oncol (R Coll Radiol). 2011 Mar;23(2):79-85. doi: 10.1016/j.clon.2010.08.031. Epub 2010 Oct 30.
To report the radiation planning dosimetric aspects and clinical outcomes of patients with implanted cardiac pacemakers.
Between 2005 and 2009, eight patients with in situ cardiac pacemakers of varied primary site were treated at our hospital. All patients underwent computed tomography-based treatment planning. The target volumes, organs at risk and pacemaker device were all contoured. A treatment plan optimally covering the target area and maximally sparing the pacemaker was generated. All patients were evaluated at baseline, during radiotherapy and after radiotherapy conclusion by a cardiologist as well as pacemaker company personnel.
The median age at presentation was 67 (range 53-77) years. There were three men with head and neck primaries, two men with lung primaries and three women with breast primaries. The prescribed dose ranged from 45 to 70 Gy in 25-35 fractions with a daily dose of 1.8-2.0 Gy. Four patients had the pacemaker implanted on the same side as the radiotherapy target. The dose ranges for the minimum, mean and maximum doses to the pacemaker were 0.06-2.0, 0.07-20.6 and 0.14-60.0 Gy, respectively. Radiation therapy was safely delivered in all patients without any untoward effects. At 5 months of median follow-up, all patients were well with no malfunction of the pacemaker.
A series of eight patients with in situ pacemakers treated with radiotherapy is reported. Radiotherapy can be safely delivered in patients with implanted cardiac pacemakers. However, it mandates a cautious approach in planning and treatment delivery to ensure the least possible dose to the pacemaker. Close liaison with the cardiologist and a pacemaker clinic before, during and after the course of treatment is essential to ensure patient safety.
报告植入式心脏起搏器患者的放射计划剂量学方面和临床结果。
2005 年至 2009 年间,我院收治了 8 例原位心脏起搏器的患者,其原发部位各不相同。所有患者均接受基于计算机断层扫描的治疗计划。目标体积、危及器官和起搏器设备均进行了轮廓勾画。生成了一个最佳覆盖目标区域且最大限度保护起搏器的治疗计划。所有患者均在基线、放射治疗期间和放射治疗结束后由心脏病专家和起搏器公司人员进行评估。
中位年龄为 67 岁(范围为 53-77 岁)。有 3 例男性头颈部原发肿瘤,2 例男性肺癌,3 例女性乳腺癌。处方剂量范围为 45-70 Gy,25-35 个分次,每日剂量为 1.8-2.0 Gy。4 例患者的起搏器与放射治疗靶区同侧植入。起搏器的最小、平均和最大剂量范围分别为 0.06-2.0、0.07-20.6 和 0.14-60.0 Gy。所有患者均安全接受放射治疗,无不良反应。中位随访 5 个月时,所有患者情况良好,起搏器无故障。
报告了 8 例原位起搏器患者接受放射治疗的一系列情况。放射治疗可以安全地用于植入心脏起搏器的患者。然而,在计划和治疗实施过程中需要谨慎处理,以确保起搏器受到的剂量尽可能小。在治疗过程前后与心脏病专家和起搏器诊所保持密切联系对于确保患者安全至关重要。